Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 8/20 | 0.50 |
| ▸ | JAK2 | O60674 | 13/20 | 0.45 |
| ▸ | JAK3 | P52333 | 7/20 | 0.45 |
| ▸ | AURKA | O14965 | 4/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | STK10 | O94804 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | FER | P16591 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | STAT5A | P42229 | 1/20 | 0.43 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.43 |
| ▸ | STK4 | Q13043 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220866 | 0.81 | JAK2 (0.61) | NTRK1JAK2JAK3AURKARET | |
| SCHEMBL29528815 | 0.76 | DHFR (0.39) | FGFR1CDK9CDK5 | |
| SCHEMBL3349894 | 0.74 | JAK2 (0.75) | NTRK1JAK2JAK3AURKARET | |
| SCHEMBL219911 | 0.74 | JAK2 (0.75) | NTRK1JAK2JAK3AURKARET | |
| SCHEMBL3349448 | 0.74 | JAK2 (0.75) | NTRK1JAK2JAK3AURKARET | |
| SCHEMBL3345053 | 0.74 | JAK2 (0.75) | NTRK1JAK2JAK3AURKARET | |
| SCHEMBL3774696 | 0.73 | NTRK1 (0.72) | NTRK1JAK2JAK3FGFR1FLT3 | |
| SCHEMBL24609025 | 0.70 | NTRK1 (0.51) | NTRK1JAK2JAK3AURKARET | |
| SCHEMBL3776063 | 0.69 | NTRK1 (0.41) | NTRK1JAK2JAK3AURKARET | |
| SCHEMBL589564 | 0.69 | NTRK1 (0.63) | NTRK1JAK2JAK3AURKARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071480-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA R&D (SE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071480-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ABL1, FLT3, ERBB2 | NTRK1 734/4885JAK2 42/4885JAK3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.